Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy

The growing field of immune metabolism has revealed promising indications for metabolic targets to modulate anti-cancer immunity. Combination therapies involving metabolic inhibitors with immune checkpoint blockade (ICB), chemotherapy, radiation, and/or diet now offer new approaches for cancer thera...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular cell Jg. 78; H. 6; S. 1019
Hauptverfasser: Bader, Jackie E, Voss, Kelsey, Rathmell, Jeffrey C
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 18.06.2020
Schlagworte:
Humans
Immunologic Factors - metabolism
Immunotherapy - methods
Immunotherapy - trends
Neoplasms - immunology
Neoplasms - metabolism
Neoplasms - therapy
Tumor Microenvironment - drug effects
Tumor Microenvironment - immunology
ISSN:1097-4164, 1097-4164
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The growing field of immune metabolism has revealed promising indications for metabolic targets to modulate anti-cancer immunity. Combination therapies involving metabolic inhibitors with immune checkpoint blockade (ICB), chemotherapy, radiation, and/or diet now offer new approaches for cancer therapy. However, it remains uncertain how to best utilize these strategies in the context of the complex tumor microenvironment (TME). Oncogene-driven changes in tumor cell metabolism can impact the TME to limit immune responses and present barriers to cancer therapy. These changes also reveal opportunities to reshape the TME by targeting metabolic pathways to favor immunity. Here we explore current strategies that shift immune cell metabolism to pro-inflammatory states in the TME and highlight a need to better replicate physiologic conditions to select targets, clarify mechanisms, and optimize metabolic inhibitors. Unifying our understanding of these pathways and interactions within the heterogenous TME will be instrumental to advance this promising field and enhance immunotherapy.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1097-4164
1097-4164
DOI:10.1016/j.molcel.2020.05.034